FOUR leading experts in the field of oncology were brought together in an interview to discuss the epidemiology, treatment decisions, and emerging treatment paradigms of EGFR-mutated advanced non-small cell lung cancer (NSCLC). Recent clinical evidence was also reviewed, including the RELAY trial.
EMJ Oncology 9 [Supplement 1] . 2021
January 2021
In this issue
Latest articles
All articles![](https://www.emjreviews.com/wp-content/uploads/2024/04/Onc-Aparna-Parikh-Interview-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/03/TN-1-1-940x564.png)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/Eugena-Stamuli-thumbnail-940x564.jpg)
![](https://www.emjreviews.com/wp-content/uploads/2024/02/GSK-ONC-010-23-2-Thumbnail-940x564.png)